Fast Facts: Biosimilars in Hematology and Oncology : Biologics and biosimilars - getting decisions right
Biologics have revolutionized - and are revolutionizing - the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days' exposure in Europe, shows that approved biosimilars...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Livre numérique |
| Langue: | Anglais |
| Publié: |
Basel :
S. Karger
2020.
Basel : |
| Accès en ligne: | https://www.karger.com/Book/Home/279159 Accès Université d'Orléans et IFPM |
| Note: |
Karger Fast Facts |
| Autres localisations: | Voir dans le Sudoc |
| Edition sous un autre format: | • Fast Facts: Biosimilars in Hematology and Oncology, 9781912776214 |
| Résumé: | Biologics have revolutionized - and are revolutionizing - the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days' exposure in Europe, shows that approved biosimilars can be used as safely and effectively as originator biologics. Yet concerns persist about biosimilars - particularly in curative cancer treatment, where they are relatively recent therapeutic options. 'Fast Facts: Biosimilars in Hematology and Oncology' provides a concise overview of emerging global practice in this fast-moving area together with practical information on adding biosimilars to a formulary and switching patients. |
|---|---|
| Description: | Karger Fast Facts |
| ISBN: | 9781912776221 |
| Accès: | Accès libre pour tout établissement ou utilisateur ayant un compte sur la plateforme de l'éditeur |